Physician profile
Swarna Byri
NPI 1871731414
$1,121.67
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61.20 · 2021: $212 · 2022: $555 · 2023: $58.33 · 2024: $235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $293.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $293.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $218.97 | 2021-2022 | |
| Baxter Healthcare | $200.31 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $162.88 | 2022-2024 | Farxiga |
| Horizon Therapeutics Plc | $113.69 | 2021-2023 | Krystexxa |
| Bard Peripheral Vascular, INC. | $94.60 | 2024 | Fluency Endovascular Stent Graft |
| Otsuka America Pharmaceutical, INC. | $77.99 | 2019-2021 | |
| Glaxosmithkline, LLC. | $67.62 | 2021-2022 | |
| Fresenius USA Marketing, INC. | $46.72 | 2021-2022 | |
| Vifor Pharma, INC. | $44.34 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $42.74 | 2022 | |
| Aurinia Pharma U.S., INC. | $26.91 | 2022 | |
| Akebia Therapeutics INC | $24.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Swarna Byri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.